09:27 AM EDT, 09/19/2025 (MT Newswires) -- Boston Scientific ( BSX ) is expected to provide a long-term organic revenue growth outlook at its upcoming investor day higher than the guidance it issued two years ago, Needham said in a Friday client note.

The medical device manufacturer is scheduled to host its biennial investor day at the end of September, and Needham anticipates the firm to unveil its financial targets for the period between 2026 and 2028, as well as provide updates on its business units, recent product launches and new product pipeline.

The brokerage estimates Boston Scientific ( BSX ) to issue compound annual growth rate guidance for organic revenue of 9% to 11%, amid its robust product cycle and healthy market growth. In 2023, the company expected a compound annual growth rate of 8% to 10% for the 2024 to 2026 period, according to Needham.

For other key metrics, including per-share earnings and adjusted operating margin improvement, Needham anticipates the company to provide targets in line with those shared at its 2023 investor day. "Overall, we expect the (2026 to 2028) guidance ranges to mostly bracket consensus estimates over the same time frame," Needham analysts, including Mike Matson, wrote in the note.

The brokerage believes Boston Scientific ( BSX ) is on track to exceed its financial targets for 2024 through 2026, based on last year's results through the first half of 2025 and guidance for the second half through next year.

Several of the medical device manufacturer's new products are expected to support robust organic revenue growth, according to Needham. The brokerage also expects product cost reductions, easing inflation, tariff mitigation and pricing initiatives to drive gross margin improvement in the next few years.

In July, the company reported better-than-expected second-quarter results and lifted its full-year outlook.

Needham reiterated its buy rating on Boston Scientific's ( BSX ) stock with a price target of $121. The brokerage said it continues to view the company as one of the "highest quality" large market capitalization medical technology firms.